Clinical trials: Untreated
Parkinson's Disease
National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial
The goal of this study is to assess the impact of minocycline and creatine on the progression of Parkinson's disease, in order to determine whether it is reasonable to proceed with further study of either of these agents.
- Trial name
- NCT00063193
- Testing
- minocycline, creatine
- Where
- United States
- Volunteers
- 195 people
- Sponsor
- University of Rochester
Type II Diabetes Mellitus
Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients
The purpose of this study is to evaluate the effect of JTT-654 on diabetes as well as the safety, tolerability and pharmacokinetics of JTT-654 in type 2 diabetic patients.
- Trial name
- NCT00997152
- Testing
- JTT-654
- Where
- 42 sites in United States
- Volunteers
- 152 people
- Sponsor
- Shionogi Inc.
Germ Cell Tumors
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
The purpose of this study is to learn about the safety and effectiveness of two different drug combinations in patients who have intermediate- and poor-risk germ cell tumors (GCT).
- Trial name
- NCT01873326
- Testing
- Paclitaxel, Ifosfamide, Cisplatin
- Where
- 13 sites in United States
- Volunteers
- 92 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
BRF113683 is a Phase III, randomized, open-label study comparing the efficacy, safety, and tolerability of GSK2118436 to dacarbazine (DTIC), in subjects with BRAF mutant advanced (Stage III) or metastatic (Stage IV) melanoma.
- Trial name
- NCT01227889
- Testing
- GSK2118436, Dacarbazine (DTIC)
- Where
- 94 sites in United States, Australia and 10 more
- Volunteers
- 251 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Non-Small-Cell Lung
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
The primary purpose of this study is to determine the safety and tolerability of the combination of bemcentinib with chemo-immunotherapy (CIT) to identify the recommended phase 2 dose (RP2D) when administered as first line (1L)…
- Trial name
- NCT05469178
- Testing
- Bemcentinib, Pembrolizumab, Pemetrexed
- Where
- 34 sites in United States, France and 5 more
- Volunteers
- 26 people
- Sponsor
- BerGenBio ASA
Acromegaly, Osteoporosis Risk
Bone MicroArchitecture in Acromegaly
The investigators will conduct a cross-sectional study of bone density, bone microarchitecture, vertebral fractures and trabecular bone score in 25 patients with acromegaly treated with Pegvisomant, the growth hormone (GH)…
- Trial name
- NCT03225040
- Testing
- Pegvisomant
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Columbia University
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma
RATIONALE: Glutamine may help prevent mucositis, or mouth sores, in patients receiving chemotherapy for sarcoma. It is not yet known whether glutamine is more effective than a placebo in preventing mucositis in patients receiving…
- Trial name
- NCT00334984
- Testing
- glutamine, chemoprotection, management of therapy complications
- Sponsor
- Children's Oncology Group
Acute Promyelocytic Leukemia
New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
The safety and efficacy of combining NRX 195183 with arsenic trioxide in treating untreated APL will be assessed.
- Trial name
- NCT00670150
- Testing
- NRX 195183 (retinoid analogue), Arsenic Trioxide
- Where
- United States
- Sponsor
- University of Southern California
Urethral Stricture, Urethral Stricture, Anterior
Treatment of Bulbar Urethral Strictures With Optilume Drug-Coated Balloons in an Untreated Population
This randomized controlled trial investigates the effectiveness and safety of the Optilume® drug-coated balloon (DCB) compared to standard direct visual internal urethrotomy (DVIU) in the treatment of bulbar urethral strictures.
- Conditions
- Urethral Stricture, Urethral Stricture, Anterior, Urethral Stricture, Male, Urethral Stricture Less Than 2 cm
- Trial name
- FIRST-CARE (NCT06827210)
- Testing
- Optilume DCB, Standard Direct Visual Internal Urethrotomy (DVIU)
- Where
- 3 sites in Denmark
- Volunteers
- 140 people
- Sponsor
- Aalborg University Hospital
Multiple Myeloma
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.
- Trial name
- NCT03652064
- Testing
- Daratumumab, Bortezomib, Lenalidomide
- Where
- 114 sites in United States, Brazil and 11 more
- Volunteers
- 395 people
- Sponsor
- Janssen Research & Development, LLC
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia
This phase I trial is studying the side effects and best dose of bortezomib when given together with decitabine in treating patients with acute myeloid leukemia.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Trial name
- NCT00703300
- Testing
- bortezomib, decitabine, pharmacological study
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
This multicenter, prospective, open-label, randomized, superiority phase 3 study is designed to demonstrate that treatment with a triple combination of acalabrutinib, obinutuzumab and venetoclax (GAVe) prolong the…
- Trial name
- NCT05197192
- Testing
- Obinutuzumab, Venetoclax, Acalabrutinib
- Where
- 30 sites in Germany
- Volunteers
- 202 people
- Sponsor
- German CLL Study Group
Metastatic Colorectal Cancer
Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer
To document the antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer.
- Trial name
- NCT00459901
- Testing
- Erlotinib and capecitabine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Peter Kozuch
Splenic Marginal Zone Lymphoma
Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients
The goal of this clinical trial is to compare the efficacy and tolerability of the combination of two medicinal products, rituximab, and zanubrutinib, compared to rituximab monotherapy in patients with Splenic Marginal Zone…
- Trial name
- RITZ (NCT05735834)
- Testing
- Rituximab, Zanubrutinib
- Where
- 49 sites in Austria, France and 6 more
- Volunteers
- 122 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Peripheral T Cell Lymphoma, Epigenetic Repression
Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
This study is investigating the effectiveness (specifically the objective response rate - ORR) of a new combination therapy called CAMP (chidamide, azacitidine, liposomal mitoxantrone, and prednisone) for previously untreated…
- Trial name
- NCT05958719
- Testing
- Chidamide, Azacitidine, liposomal mitoxantrone
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Lymphoma, Mantle Cell Lymphoma
A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
To learn if giving acalabrutinib, rituximab, and brexucabtagene autoleucel to patients with previously untreated high-risk mantle cell lymphoma (MCL) can help to control the disease.
- Trial name
- NCT05495464
- Testing
- Acalabrutinib, Rituximab, Brexucabtagene Autoleucel
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer
This is a Phase II study of the drug combination of Oxaliplatin, Avastin and capecitabine. This is an open-label study.
- Trial name
- NCT00177307
- Testing
- Bevacizumab, Capecitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Pittsburgh
Lung Cancer, Non-Small Cell
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells [TC]/ Tumor proportion score [TPS] >= 50%), previously untreated, unresectable…
- Trial name
- NCT05565378
- Testing
- Pembrolizumab, Dostarlimab, Belrestotug
- Where
- 99 sites in United States, Argentina and 20 more
- Volunteers
- 351 people
- Sponsor
- GlaxoSmithKline
Diffuse Large B-Cell Lymphoma
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
The purpose of this study is to compare the efficacy and safety of genotype-guided targeted agents in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola RCHP-X) versus Pola…
- Trial name
- NCT06803693
- Testing
- Polatuzumab vedotin, Rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Ruijin Hospital
Unresectable, Recurrent or Metastatic Melanoma, Untreated Mucosal or Acral Lentiginous Melanoma
A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma
This is an open-label, multi-cohort, multi-center Phase I clinical trial to evaluate the efficacy and safety of MGD013 in ① Cohort 1: patients with unresectable, recurrent or metastatic melanoma who have failed prior immune…
- Trial name
- NCT04653038
- Testing
- MGD013
- Where
- 13 sites in China
- Volunteers
- 92 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.